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Abstract
Glycine, a nonessential amino-acid that acts as an inhibitory neurotransmitter in the central nervous system, is currently
used as a dietary supplement to improve the quality of sleep, but its mechanism of action is poorly understood. We
confirmed the effects of glycine on sleep/wakefulness behavior in mice when administered peripherally. Glycine
administration increased non-rapid eye movement (NREM) sleep time and decreased the amount and mean episode
duration of wakefulness when administered in the dark period. Since peripheral administration of glycine induced
fragmentation of sleep/wakefulness states, which is a characteristic of orexin deficiency, we examined the effects of glycine
on orexin neurons. The number of Fos-positive orexin neurons markedly decreased after intraperitoneal administration of
glycine to mice. To examine whether glycine acts directly on orexin neurons, we examined the effects of glycine on orexin
neurons by patch-clamp electrophysiology. Glycine directly induced hyperpolarization and cessation of firing of orexin
neurons. These responses were inhibited by a specific glycine receptor antagonist, strychnine. Triple-labeling
immunofluorescent analysis showed close apposition of glycine transporter 2 (GlyT2)-immunoreactive glycinergic fibers
onto orexin-immunoreactive neurons. Immunoelectron microscopic analysis revealed that GlyT2-immunoreactive terminals
made symmetrical synaptic contacts with somata and dendrites of orexin neurons. Double-labeling immunoelectron
microscopy demonstrated that glycine receptor alpha subunits were localized in the postsynaptic membrane of
symmetrical inhibitory synapses on orexin neurons. Considering the importance of glycinergic regulation during REM sleep,
our observations suggest that glycine injection might affect the activity of orexin neurons, and that glycinergic inhibition of
orexin neurons might play a role in physiological sleep regulation.
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Introduction
As the primary inhibitory neurotransmitter in the central
nervous system, glycine is widely distributed throughout the
brainstem and spinal cord [1,2,3]. It also acts as an allosteric
modulator of the N-methyl-D-aspartate (NMDA) receptor [4,5].
Glycine is thought to play important roles in sleep regulation.
Especially, medullary glycinergic neurons were shown to inhibit
somatic motor neurons during REM sleep [6,7,8,9].
It was also reported that orally administered glycine increased
subjective sleep quality without any adverse effect [10]. However,
the mechanisms and sites of action of these effects of glycine
administration on sleep have remained largely unclear.
In the present study, we confirmed the effect of glycine on
sleep/wakefulness states in mice. Notably, glycine not only
decreased wakefulness time in the dark period, but also
significantly shortened the mean wakefulness duration, suggesting
fragmentation of sleep/wakefulness states. Since fragmentation of
sleep/wakefulness states is one of the characteristics of orexin-
deficiency, we examined whether glycine influences the activity of
orexin-producing neurons, which play highly important roles in
sleep/wakefulness regulation [11]. We found that peripheral
administration of glycine decreased the activity of orexin neurons
as examined by Fos-immunoreactivity. We also identified the
existence of functional glycine receptors and glycinergic synapses
in orexin neurons by electrophysiology, immunofluorescence and
immunoelectron microscopy.
Results
Sleep/wakefulness States were Influenced by
Intraperitoneal Glycine Administration in Mice
Although glycine ingestion is reported to affect subjective sleep
quality in humans [10], it is not known whether it actually affects
sleep/wakefulness states in mice. Therefore, we first examined the
effects of glycine on sleep/wakefulness states in mice. Sleep state
patterns in mice were examined by simultaneous EEG/EMG
recording after glycine administration. Mice were administered
glycine (2 g/kg) or saline intraperitoneally 10 min before light on
(ZT0) or off (ZT12), and then subjected to simultaneous EEG/
EMG recording for 5 hours (Fig. 1A). In the light period, the
pattern of sleep/wakefulness states was not statistically significantly
different between the saline- and glycine-administered groups with
respect to the total time, mean durations and stage count for all
vigilance states (Fig. 1B,D,F).
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e25076Figure 1. Glycine-induced sleep phenotype during dark period. A Protocols for glycine administration in light (left panel) or dark period
(right panel). Glycine or saline was injected intraperitoneally 10 min before the start of recording (ZT0 or ZT12). EEG/EMG recordings were performed
for the next 5 hours (until ZT5 or ZT17). B, C Total time (minutes, mean 6 SEM) spent in each state in saline- (n=4, white bar) and glycine-
administered mice (n=4, gray bar), itemized separately for light (B) and dark periods (C). D, E Episode duration (seconds, mean 6 SEM) spent in each
state in saline- and glycine-administered mice, in light (D) or dark period (E). F, G Stage count (count, mean 6 SEM) is number of each episode during
each period (light; F, dark; G). The glycine-administered group showed a significantly shorter total time and duration of episodes of wakefulness,
suggesting fragmentation of sleep/wakefulness states during the dark period. *p,0.015. Graphs summarize the data recorded during the 5 h light/
dark period.
doi:10.1371/journal.pone.0025076.g001
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significant impact on the sleep/wakefulness states of mice in the
dark period. There were marked differences between the saline-
and glycine-administered groups in the amount of both wakeful-
ness and NREM sleep, duration of wakefulness state, and stage
count of both wakefulness and NREM sleep in the dark period
(Fig. 1C,E,G). These observations suggest that glycine decreased
wakefulness time and increased NREM sleep time in mice when
administered at the start of the dark period. Notably, glycine
administration resulted in marked shortening of the mean episode
duration of wakefulness, accompanied by increased stage count of
both wakefulness and NREM sleep (Fig. 1E,G, supplementary Fig.
S1). These observations indicate that glycine administration in the
dark period decreased the stability of sleep/wakefulness states, and
induced sleep/wakefulness fragmentation in mice.
Activity of Orexin Neurons is Decreased by
Intraperitoneal Glycine Administration
Fragmentation of sleep/wakefulness states in the dark period is
one of the hallmarks of orexin deficiency or narcolepsy in many
mammalian species [11]. Therefore, we next examined the
possibility that peripherally-administered glycine influences the
activity of orexin neurons. Mice were intraperitoneally adminis-
tered glycine (2 g/kg B.W.) or saline at ZT0 and ZT12, and then
killed 3 hours after administration at ZT3 and ZT15 (Fig. 2A).
Brain slices of mice with or without glycine administration were
examined by double staining with anti-orexin and anti-Fos
antibodies to assess the activity of these orexin neurons. In control
mice, the percentage of double-labeled neurons (orexin-positive
neurons with Fos-positive nuclei) showed marked diurnal fluctu-
ations, with a lower level of double-labeling at ZT3 (n=3,
12.161.8%, mean 6 SEM) and higher level at ZT15 (n=4,
67.264.2%, mean 6 SEM) (Fig. 2B,C,F), as reported previously
in rats [12]. Glycine administration significantly decreased the
percentage of Fos-positive orexin neurons to 4.261.5% (n=4,,
mean 6 SEM, t5=3.412, p=0.019) and 26.262.0% (n=6, mean
6 SEM, t8=9.880, p,0.0001) at ZT3 and ZT15, respectively
(Fig. 2D,E,F). Range of orexin cell numbers and c-fos positive cell
numbers were shown as supplementary table S1.
Glycine Inhibits Orexin Neurons in Vitro
Since we found that peripheral administration of glycine
decreased the activity of orexin neurons, we next examined
whether glycine directly inhibits orexin neurons. We carried out
whole-cell current-clamp recordings on acute slice preparations of
orexin/EGFP transgenic mice [13]. Under whole-cell current clamp
mode, glycine (1 mM) bath application hyperpolarized orexin
neurons, with a decrease in firing frequency (Fig. 3A). Hyperpo-
larization was also observed in the presence of TTX (Fig. 3A),
suggesting that glycine directly inhibits orexin neurons. The
response peaked 30–60 sec after application of glycine, and the
membrane potential returned to the basal level 2–3 min after
washout. The majority of GFP-positive neurons tested were
hyperpolarized by glycine (89%, 33 out of 37), and a few orexin
neurons showed no response (11%, 4 out of 37). Figure 3B
demonstrates that glycine-induced inward currents recorded in a
voltage-clamp at 260 mV were concentration-dependent; EC50
and maximum effect (Emax) were 10
23.0060.17 M and 20565 pA,
respectively (n=2–3). Additionally, glycine (1 mM)-induced hy-
perpolarization was significantly inhibited by strychnine (1 mM),
suggesting that the inhibitory effect is dependent on the ionotropic
glycine receptor (GlyR) (Fig. 3C). The reversal potential estimated
from the I–V relationship was 280.662.4 mV (n=3), which is
near the theoretically obtained value of this parameter for Cl
2
(277.5 mV at 25uC) (Fig. 3D, E). This value is similar to that of
the theoretical Cl
2-selective ion channel calculated by the Nernst
equation, in agreement with known biophysical properties of GlyR
Cl
2 channels.
Existence of Glycinergic Synapses in Orexin Neurons
The responsiveness of orexin neurons to glycine suggests the
possibility that these neurons are physiologically regulated by
glycinergic neurotransmission. To address this possibility, we
produced specific antibodies against bacterial fusion proteins
encoding the glycine receptor common to all four a subunits
(GlyRa) and plasmalemmal glycine transporter 2 (GlyT2). By
immunoblotting, GlyRa antibody recognized protein bands at
around 45 kDa in both HEK293 cell lysates expressing mouse
GlyRa subunits and adult mouse brain, but not in HEK293 cell
lysates transfected with plasmid vector only or expressing mouse
GlyRb subunit (Fig. 4A). GlyT2 antibody selectively recognized a
broad protein band at around 75 kDa in HEK293 cell lysates
expressing mouse GlyT2, and at 90 kDa in adult mouse brain
(Fig. 4A). On immunofluorescence, both antibodies mainly labeled
the lower brainstem (Fig. 4B, F), while those preabsorbed with
antigens yielded blank labeling (Fig. 4C, G). Immunoreactivity of
these antibodies was further characterized by immunoelecrtron
microscopy of the facial nucleus. Double-labeling with postembed-
ding immunogold for GlyRa and vesicular inhibitory amino acid
transporter (VIAAT) revealed that the postsynaptic membrane
was consistently labeled for GlyRa at symmetrical synapses (95%;
20 out of 21 synapses), but not asymmetrical synapses (0%; 0 out of
15 synapses) (Fig. 4D). The mean number of immunogold particles
per contact site was 4.9+4.7 (mean + SD) in dendites of facial
nucleus neurons. Preembedding immunoelectron microscopy also
showed that immunoparticles for GlyT2 were selectively associ-
ated with presynaptic terminals forming symmetrical synapses
(100%, 10 out of 10 terminals), but not asymmetrical synapses
(0%, 0 out of 10 terminals) (Fig. 4H). As symmetrical and
asymmetrical synapses are considered to mostly, if not totally,
represent inhibitory or excitatory synapses, respectively, these
results indicate the specificity of the produced GlyRa and GlyT2
antibodies and their usefulness to identify glycinergic synapses.
Although the overall immunofluorescence intensity was much
lower in the hypothalamus than in the lower brainstem (Fig. 4B,
F), punctate labeling of GlyT2 and GlyRa did exist around GFP-
positive orexin neurons in the lateral hypothalamic area (LHA)
(Fig. 5A, D). At higher magnification, almost all somata [95% (36
out of 38)] and proximal dendrites [95% (19 out of 20)] of GFP-
positive orexin neurons were associated with GlyT2-positive
varicosities (Fig. 5B, C). Since glycinergic terminals require
VIAAT for glycine filling into synaptic vesicles, we further
examined if GlyT2-positive varicosities on orexin neurons co-
expressed VIAAT (Fig. 5B, C). Indeed, VIAAT coexisted in most
GlyT2-positive varicosities associated with somata [85% (49 out of
58)] or proximal dendrites [84% (38 out of 45)], suggesting the
formation of glycinergic synapses. To confirm this at the electron
microscopic level, we employed double-labeling immunoelectron
microscopy for GlyT2 (dark precipitates of DAB) and GFP (metal
particles) (Fig. 6). Analysis of serial ultrathin sections revealed that
GlyT2-positive glycinergic varicosities occasionally contacted
somata (Fig. 6A) and proximal dendrites (Fig. 6B) of GFP-positive
orexin neurons. At contact sites, both sides of the apposed
membranes had electron-dense material and were spaced with a
cleft of uniform width, thus being judged to be a symmetrical
synaptic junction (Fig. 6). For quantitative analysis, we randomly
selected GFP-positive profiles of somata and dendrites, and
examined if they had such synaptic contacts with GlyT2-positive
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PLoS ONE | www.plosone.org 3 September 2011 | Volume 6 | Issue 9 | e25076Figure 2. Effects of glycine administration to mice on activity of orexin neurons. A. Protocols for glycine administration in light (left panel)
or dark period (right panel). Glycine or saline was injected intraperitoneally at ZT0 or ZT12, and then mice were sacrificed at ZT3 or ZT15. B–E,
Representative immunohistochemical micrographs of double-staining with anti-c-Fos (black) and anti-orexin A (brown) antibody at ZT3 (B, control
(saline); D, glycine (2 g/kg)) and at ZT15 (C, control; E, glycine). White arrowheads show orexin-immunoreactive cells. Black arrowheads show orexin
neurons with Fos-immunoreactivity in their nuclei. Scale bar, 20 mm. F. Percentage of c-Fos-expressing orexin neurons at ZT 3 (control; n=3, glycine;
n=4) and ZT 15 (control; n=4, glycine; n=6). Values are mean 6 SEM. *p,0.02, **p,0.0001.
doi:10.1371/journal.pone.0025076.g002
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found that 31% (4 out of 13) of GFP-positive somata and 23% (13
out of 65) of GFP-positive dendrites had synaptic contact with
GlyT2-positive varicosities, all of which were judged to be
symmetrical synapses. These results confirm the existence of
symmetrical synaptic junctions between glycinergic terminals and
GFP-positive orexin neurons.
We next examined if glycine receptors accumulated at such
symmetrical synaptic junctions. GlyRa-positive puncta were
frequently detected on the surface of GFP-positive orexin neurons,
and were tightly paired with VIAAT-positive varicosities (Fig. 5E,
F). Such co-localization was observed in 71% (12 out of 17) and
82% (9 out of 11) of somata and proximal dendrites, respectively,
of GFP-positive neurons. By double-labeling postembedding
immunogold for GlyRa (10 nm in diameter) and orexin A
(15 nm), we found immunogold particles for GlyRa at symmet-
rical synapses on neuronal somata, whose Golgi apparatus was
heavily labeled for orexin A (Fig. 7A). For quantitative analysis, we
Figure 3. Glycine directly inhibits orexin neurons. A. Under whole-cell current-clamp mode, glycine (1 mM) was applied to orexin neurons in
normal extracellular solution, in the absence of TTX (upper panel), in the presence of TTX (1 mM) (middle panel) and in the presence of both TTX
(1 mM) and strychnine (1 mM) (lower panel). Glycine was applied during the period indicated by the bars. B. Concentration dependency of glycine-
induced outward currents in orexin neurons clamped at 260 mV. EC50 and Emax were 10
23.0060.17 M and 20565 pA, respectively (n=2–3). C.
Strychnine (1 mM) significantly inhibited the effect of glycine in the presence of TTX. D. Records of membrane potential in response to a series of
current steps (from 2150 to +120 pA in 30 pA increments) from resting potential (260 mV) in the absence (left) or presence (right) of glycine
(10 mM). E. Current-voltage relationship derived from the data in F. The potential at the end of current injection was plotted; control (open circles)
and 10 mM glycine (filled circles). Estimated reversal potential was 280.5 mV (n=3). Values are mean 6 SEM.
doi:10.1371/journal.pone.0025076.g003
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PLoS ONE | www.plosone.org 5 September 2011 | Volume 6 | Issue 9 | e25076Figure 4. Specificity of GlyRa and GlyT2 antibodies. A, E. Immunoblotting using GlyRa and GlyT2 (E) antibodies. Each lane was loaded with
HEK293 cell lysates transfected with expression plasmid only (mock), transfected with expression plasmid encoding GlyRa1, GlyRa3, GlyRa4, GlyRb,o r
GlyT2, and adult mouse brain homogenates. Because of low viability, HEK293 cell lysate of GlyRa2-transfected cells was omitted. Identical patterns of
immunoblot labeling were repeatedly confirmed in three independent experiments. The position of protein size markers (kDa) is shown on the left. B,
C, F, G. Immunofluorescence with use of GlyRa (B, C) or GlyT2 (F, G) in parasagittal brain sections. Note that preincubation of antibodies with antigen
protein (C, G) almost completely abolished immunostaining. D. Double-labeling postembedding immunogold for GlyRa (10 nm) and VIAAT (15 nm)
in the facial nucleus. Note that GlyRa localizes to a symmetrical synapse (black arrowheads) made with a VIAAT-positive inhibitory terminal (In), but
not to an asymmetrical synapse (white arrowheads) made with a VIAAT-negative excitatory terminal (Ex). Arrows indicate immunogold particles for
GlyRa. H. Preembedding silver-enhanced immunoelectron microscopy of facial nucleus. Metal particles for GlyT2 are preferentially distributed on the
cell membrane of presynaptic inhibitory terminals (In), which contain flat synaptic vesicles and make symmetrical synapses with dendritic shafts (Dn).
OB, olfactory bulb; Cx, cerebral cortex; St, striatum; Th, thalamus; Ht, hypothalamus; Mb, midbrain; Po, pons; Cb, cerebellum; MO, medulla oblongata;
Ex, excitatory terminal; In, inhibitory terminal; Dn, dendrite. Scale bars, B, C, F, G; 1 mm; D, H, 400 nm.
doi:10.1371/journal.pone.0025076.g004
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which postembedding immunogold for VIAAT (20 nm) and
GlyRa (10 nm) was applied to LHA sections that had been
subjected to immunoperoxidase for GFP (dark precipitates of
DAB). Somata and proximal dendrites of GFP-positive neurons
showed frequent contacts with VIAAT-positive terminals
(Fig. 7B,C). Occasionally, their contact sites were labeled for
GlyRa; immunogold particles for GlyRa were detected in 13% (3
out of 23) and 26% (12 out of 46) of contact sites in GFP-positive
somata and dendrites, respectively. The mean number of
immunogold particles per contact site was 0.1360.34 in somata
and 0.5260.96 in dendites of GFP-positive orexin neurons. Taken
together, these observations indicate that the glycine receptor is
expressed in glycinergic synapses in orexin neurons.
Figure 5. Immunofluorescence showing glycinergic innervations to orexin neurons. A. Double immunofluorescence showing distribution
of GlyT2-positive glycinergic varicose fibers (red) and GFP-positive orexin neurons (green) in the LHA. B, C. Triple immunofluorescence showing that
orexin neurons (GFP, green) are associated with GlyT2-positive (red)/VIAAT-positive (blue) varicosities (arrows). D. Double immunofluorescence
showing the distribution of GlyRa- (red) and GFP-positive orexin neurons (green) in the LHA. E, F. Orexin neurons (green) display numerous VIAAT-
positive inhibitory terminals (blue), some of which are associated with GlyRa immunoreactivity (red) on the surface of orexin neurons. Scale bars,
10 mm.
doi:10.1371/journal.pone.0025076.g005
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Glycine, an inhibitory neurotransmitter, has been implicated in
the physiological regulation of sleep. Particularly, glycinergic
neurons in the brainstem play important roles in inhibition of
alpha-motor neurons in the spinal cord during REM sleep [9]. A
glycine receptor antagonist, strychnine, was also reported to
reduce the inhibition of sensory inflow via the dorsal spinocere-
bellar tract during REM sleep [14,15,16]. Orally-administered
glycine was reported to have a beneficial effect on sleep in humans
[10]. This suggests that peripherally-administered glycine might
act on neuronal systems that play important roles in sleep
regulation.
Orexins are neuropeptides, produced by neurons in the LHA,
which send projections to all over the central nervous system
except the cerebellum. The finding that orexin deficiency causes
narcolepsy in humans and animals highlights that these hypotha-
lamic neuropeptides play a critical role in regulating sleep/
wakefulness states [11].
In the present study, we first confirmed the effect of glycine
administration on sleep/wakefulness states in mice. We found that
peripheral administration of glycine significantly decreased
wakefulness time, and caused sleep/wakefulness fragmentation in
the dark period (Fig. 1). Therefore, we investigated the effects of
glycine on orexin neurons, because orexin plays highly important
roles in maintenance of wakefulness, and deficiency of orexin
signaling has been shown to result in sleep/wakefulness fragmen-
tation, a characteristic of narcolepsy [11]. By immunohistochem-
ical study, we found that the number of Fos-positive orexin
neurons in glycine-treated mice was significantly lower at both
ZT3 and ZT15 as compared with that in saline-treated mice at the
same times (Fig. 2).
The percentage of Fos-positive orexin neurons has been
shown to correlate positively with the amount of wakefulness
and negatively with the amounts of NREM and REM sleep
[12,17]. We recently found that specific pharmacogenetic
inhibition of orexin neurons during the active period decreased
wakefulness time and increased NREM sleep time in the dark
Figure 6. Immunoelectron microscopy showing glycinergic synapse formation on orexin neurons. Consecutive images from double-
labeling preembedding immunoelectron microscopy for GFP (silver-intensified immunogold) and GlyT2 (immunoperoxidase). Note that a GlyT2-
positive terminal (filled with diffuse DAB precipitates) makes a symmetrical synaptic junction (arrowheads) onto the soma (A) and dendritic shaft (B)
of a GFP-positive orexin neuron. Scale bar, 500 nm.
doi:10.1371/journal.pone.0025076.g006
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ingested glycine might affect sleep states through inhibiting
orexin neuronal activity, although it remains unknown whether
peripherally-administered glycine can act on orexin neurons in
the LHA, or it indirectly affects the activity of these neurons.
For example, extracellular serotonin levels are reported to be
increased after oral administration of glycine [19]. Since we
found serotonin directly inhibits orexin neurons [20], glycine
administration might partly inhibit orexin neurons through
serotonin.
Figure 7. Postembedding immunogold showing glycine receptor localization at symmetrical synapses. A. Double-labeling
postembedding immunogold for GlyRa (small particles) and orexin A (large particles) shows that an orexin neuron, whose Golgi apparatus is
heavily labeled with immunogold for orexin-A (A3), expresses GlyR at a symmetrical synapse (black arrowheads, A2). B,C. Triple-labeling
immunoelectron microscopy for GFP (dark precipiates by preembedding immunoperoxidase), GlyRa (10 nm, postembedding immunogold) and
VIAAT (20 nm, postembedding immunogold). GlyRa is localized to contact sites made between VIAAT-positive inhibitory terminals (In) and the soma
(B2) or dendritic shaft (Dn, C) of GFP-positive orexin neurons. Scale bars, 1 mmi nB 1, 400 nm in A,B2,C.
doi:10.1371/journal.pone.0025076.g007
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in orexin neurons in both the light and dark periods. However,
we only observed a significant effect of glycine administration on
sleep/wakefulness states in mice in the dark period. This
observation is consistent with the previous observations that
orexin-deficient mice showed fragmentation of sleep/wakeful-
ness states only during the dark period [12,21,22]. Numbers of
orexin neurons after glycine administration were not different
from that of after saline administration as shown in supplemen-
tary table S1. This suggests that glycine did not decrease number
of orexin neurons, and glycine does not show harmful effects on
these cells.
We found that glycine can directly inhibit orexin neurons in
vitro. In the whole-cell current-clamp, most orexin neurons tested
in this experiment were potently hyperpolarized by glycine in a
concentration-dependent manner (Fig. 3). The response was
blocked by a specific glycine receptor antagonist, strychnine.
Karnani et al. also reported similar results recently [23].
Furthermore, we have demonstrated the expression of GlyR at
glycinergic synapses in orexin neurons (Figs. 5, 6). These
observations provide a functional and molecular basis for
physiological glycinergic regulation of orexin neurons. However,
this does not necessarily mean that peripherally administered
glycine directly inhibits orexin neurons. The humoral and/or
neuronal pathways that mediate glycine-induced inhibition of
orexin neurons should be further confirmed in future studies.
It should also be noted that glycine might affect arousal not only
by inhibiting orexin neurons. Systemic glycine might increase sleep
duration also through action on other arousal controlling regions
in the brain, such as monoaminergic/cholinergic neurons in the
brain stem. The contribution of orexin neurons to this effect
should be confirmed by studies using spatially restricted knock-out
GlyR in mice.
In any case, the existence of GlyR in orexin neurons suggests
the possibility that orexin neurons are physiologically regulated by
glycinergic neurotransmission. Indeed, we identified glycinergic
innervations that made synapses onto orexin neurons by means of
immunofluorescent staining and immunoelectron microscopy
(Figs. 5–7). This observation suggests the possible existence of
physiological glycinergic regulation of orexin neurons.
Glycinergic neurons in the brainstem were shown to play
important roles in inhibition of somatic motor neurons in the
spinal cord during REM sleep to evoke REM-atonia. The
activity of orexin neurons was shown to be decreased during
both NREM and REM sleep [24,25,26]. These observations
suggest an intriguing possibility that glycinergic innervations to
orexin neurons might play a role to inhibit the discharge of
orexin neurons during REM sleep, although the origin of
glycinergic fibers innervating orexin neurons in the LHA
remains unknown. Further study using selective deletion of
glycine receptor gene(s) in orexin neurons, and antero- and/or
retrograde tracer studies would be necessary to evaluate this
hypothesis.
Many factors have been identified to regulate orexin neurons,
suggesting that orexin neurons undergo regulation by a number of
physiological factors [11]. In the present study, we identified that
glycine also affects the activity of orexin neurons, when
administered peripherally. Furthermore, we identified synaptic
connections between glycinergic fibers and orexin neurons,
suggesting the possibility that orexin neurons are also physiolog-
ically regulated by glycinergic neurotransmission.
This study adds further clues to understand the precise
regulatory mechanism of orexin neurons.
Materials and Methods
Animals
All experimental procedures involving animals were conducted
with the approval of the Kanazawa University Animal Care and
Use Committee and the Hokkaido University Animal Welfare
Committee, and were in accordance with NIH guidelines. All
efforts were made to minimize animal suffering and to limit the
number of animals used. Mice were housed under controlled
lighting (12 h light-dark cycle; light on at 8:45 a.m., off at 8:45
p.m.) and temperature conditions. Food and water were available
ad libitum.
Drugs and method of administration
For in vivo experiments, glycine (2 g/kg saline) or saline alone
was injected intraperitoneally (ip) into adult male mice C57BL/6J
(10–12 weeks old, weight 20–25 g; Charles River Laboratories,
Kanagawa, Japan), at zeitgeber time (ZT) ZT0 or ZT12; ZT0 is
morning light onset. The dose of glycine was selected baed on a
previous report [19]. Three hours after administration, at ZT3
and ZT15, mice were anesthetized with sodium pentobarbital
(50 mg/kg, ip). The drugs used for electrophysiological studies
were tetrodotoxin (TTX) (Wako, Osaka, Japan), glycine (Wako),
and the glycine receptor antagonist, strychnine (Sigma-Aldrich
Corp., St. Louis, MO), which were dissolved in extracellular
solution.
Sleep recording
Male C57BL/6J mice (10–12 weeks old, 20–25 g at the time of
surgery) were prepared for chronic monitoring of EEG/EMG
signals using a lightweight implant and cabling procedure. Full
details of this technique have been published previously [27].
Immediately after surgery, mice were housed singly for a recovery
period of one week. Then, EEG/EMG recording for two
consecutive 24-h periods, beginning at light on at 08:45 and light
off at 20:45, was performed. Glycine was administered (ip) 10 min
before light on (ZT0) or off (ZT12) to mice, before they were
subjected to sleep recording for 5 hours.
Electrophysiological recordings
Orexin/EGFP mice were used for whole cell recordings [13]. The
slices were transferred to a recording chamber (RC-27L, Warner
Instrument Corp., CT, USA) at room temperature on a
fluorescence microscope stage (BX51WI, Olympus, Tokyo,
Japan). Neurons that showed GFP fluorescence were used for
patch-clamp recordings. The fluorescence microscope was
equipped with an infrared camera (C-3077, Hamamatsu Photon-
ics, Hamamatsu, Japan) for infrared differential interference
contrast (IR-DIC) imaging and a CCD camera (JK-TU53H,
Olympus) for fluorescent imaging. Each image was displayed
separately on a monitor. Recordings were carried out with an
Axopatch 700B amplifier (Axon Instruments, Foster City, CA)
using a borosilicate pipette (GC150-10, Harvard Apparatus,
Holliston, MA) prepared with a micropipette puller (P-97, Sutter
Instruments, Pangbourne, UK) and filled with intracellular
solution (4–10 MV), consisting of (mM): 125 K-gluconate, 5
KCl, 1 MgCl2, 10 HEPES, 1.1 EGTA-Na3, 5 MgATP, 0.5
Na2GTP, pH 7.3 with KOH. Osmolarity of the solution was
checked with a vapor pressure osmometer (model 5520, Wescor,
Logan, UT). The osmolarity of the internal and external solutions
was 280–290 and 320–330 mOsm/l, respectively. The liquid
junction potential of the patch pipette and perfused extracellular
solution was estimated to be 216.2 mV and was applied to the
data. The recording pipette was under positive pressure while it
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0.5–1.0 GV was made by applying negative pressure. The
membrane patch was then ruptured by suction. The series
resistance during recording was 10–25 MV and was compensated.
The reference electrode was an Ag-AgCl pellet immersed in bath
solution. During recordings, cells were superfused with extracel-
lular solution at a rate of 1.0–2.0 ml/min using a peristaltic pump
(K.T. Lab, Japan) at RT. We adjusted the resting membrane
potential of cells to around 260 mV by injecting current of 220
to 40 pA before application of glycine.
Antibodies
Primary antibodies used in this study were guinea-pig anti-
orexin antibody (1:2000) [28], rabbit anti-Fos antibody (1:20,000)
(Ab-5, Calbiochem, Darmstadt, Germany), rabbit anti-green
fluorescent protein (GFP) [29], rabbit anti-vesicular inhibitory
amino acid transporter (VIAAT) [30], guinea pig anti-glycine
receptor a-subunits (GlyRa), guinea pig and rabbit anti-glycine
transporter 2 (GlyT2), and rabbit anti-orexin-A antibodies. GlyRa
and GlyT2 antibodies were produced against glutathione S-
transferase (GST) fusion proteins containing 105–134 amino acid
residues of mouse GlyRa1 (GeneBank, NM_020492), which is
common to all four GlyRa, and 1–30 residues of mouse GlyT2
(AF411042). Orexin A antibody was produced against Keyhole
limpet hemocyanin-conjugated synthetic peptide of mouse orexin-
A (54–65 residues, NM_010410). Specific antibodies were affinity-
purified using GST-free or carrier-free peptides. The specificity of
GlyRa and GlyT2 antibodies was tested by immunoblotting using
HEK cell lysates transfected with pTracer (Invitrogen) and pEF-
BOS [31] mammalian expression vectors encoding GlyRa,
GlyRb,or GlyT2, respectively.
Immunohistochemistry
Mice were fixed transcardially with 4% paraformaldehyde in
0.1 M sodium phosphate buffer (pH 7.2, PB) followed by 4 hr
postfixation at 4uC. For Fos immunostaining, sections of fixed
brains were cut into 40-mm-thick coronal sections. For orexin and
c-Fos double staining, sections were incubated with anti-orexin
antibody and anti-Fos antibody for 24 hr at 4uC. Sections were
then incubated with biotinylated goat anti-rabbit IgG (1:1,000;
Vector Laboratories, Burlingame, CA, USA) for 1 hr at room
temperature. Tissue was then reacted with avidin-biotin complex
(Vectastain ABC Elite kit; Vector Laboratories, Burlingame, CA,
USA) for 1 hr, and Fos-immunoreactive (IR) nuclei were
visualized by reaction with 3,39-diaminobenzidine hydrochloride
(DAB) solution containing 0.003% H2O2 and 0.05% nickel
chloride to obtain a black reaction product. After c-Fos staining,
the sections were incubated with biotinylated-goat anti-guinea-pig
IgG antibody (1:1000; Vector Laboratories) for 1 hr at room
temperature. The sections were next incubated for 30 min with
Vectastain ABC Elite reagents, rinsed, and stained in 0.05% DAB
without 0.05% nickel chloride to obtain a cytoplasmic brown
reaction product. For immunofluorescent staining, orexin/EGFP
mouse brain sections were first subjected to pepsin pretreatment
for antigen exposure, i.e., incubation in 1 mg/ml pepsin (DAKO,
Carpinteria, CA) in 0.2 N HCl for 2–3 min at 37uC. Sections were
incubated successively with 10% normal donkey serum for
20 min, primary antibodies to GFP, GlyT2 or GlyRa, and
VIAAT (1 mg/ml for each) overnight, and a mixture of Alexa 488-
, Cy3- or Cy5-labeled species-specific secondary antibodies for
2 hr at a dilution of 1:200 (Invitrogen; Jackson ImmunoResearch).
Images were obtained with a confocal laser scanning microscope
FV1000 (Olympus). Z-stacks 6 to 8 mm thick composed of 1-mm-
thick optical sections were obtained with a 606oil-immersion lens.
Cell counts
A single examiner, who was blinded to treatment conditions,
performed all counts using a microscope (AX-70, Olympus
Optical). Fos-IR nuclei, orexin-IR neurons, and double-labeled
neurons were counted on both sides of the brain in nine
consecutive sections that covered the entire hypothalamus. The
percentage of double-labeled cells for each animal (double-labeled
neurons/orexin-IR neurons) was calculated as a measure of orexin
neuron activity.
Immunoelectron microscopy
Orexin/EGFP mice were fixed transcardially with 4% parafor-
maldehyde in PB (pH 7.2) for 10 min, and postfixed at 4uC for
4 hr. For postembedding immunogold, microslicer sections
(400 mm) were made using a microslicer (VT1000S, Leica). For
triple-labeling postembedding immunogold, microslicer sections
were first subjected to immunoperoxidase of GFP labeling;
sections were incubated successively with 10% normal donkey
serum for 20 min, and goat anti-GFP overnight at room
temperature. Sections were further incubated with biotinylated
donkey anti-goat IgG (Jackson ImmunoResearch) for 2 hr, and
streptavidin-peroxidase complex for 1 hr (Nichirei). Immunoreac-
tion was visualized with DAB. Sections with or without preceding
immunoperoxidase were cryoprotected with 30% glycerol in PB,
and frozen rapidly with liquid propane in the EM CPC unit (Leica
Microsystems). Frozen sections were immersed in 0.5% uranyl
acetate in methanol at 290uC in the AFS freeze-substitution unit
(Leica Microsystems), infiltrated at 245uC with Lowicryl HM-20
resin (Chemische Werke Lowi), and polymerized with UV light.
Ultrathin sections on nickel grids were etched with saturated
sodium ethanolate solution for 1–5 s, and treated successively with
blocking solution [2% normal goat serum (Nichirei) in 0.03%
Triton X-100 in Tris-buffered saline (TBST; pH 7.4)] for 20 min,
anti-GlyRa (20 mg/ml) diluted with the same blocking solution
overnight, and colloidal gold (10 nm)-conjugated goat anti-guinea-
pig IgG (1:100, British BioCell International) for 2 hr. After
washing with TBST, grids were incubated with 2% normal guinea
pig serum for 20 min in TTBST, rabbit anti-VIAAT or anti-
orexin A (20 mg/ml), diluted with the same blocking solution
overnight, followed by colloidal gold (15 nm)-conjugated goat anti-
rabbit IgG (1:100, British BioCell International) for 2 hr. Finally,
grids were fixed with 2% glutaraldehyde in PB for 15 min and 1%
OsO4 for 20 min, and stained with 2% uranyl acetate for 10 min
and Reynold’s lead citrate solution for 1 min.
For double-labeling preembedding immunoelectron microscopy,
microslicer sections were incubated in 5% bovine serum albumin
(BSA)/0.02% saponin/PBS for 30 min and then with a mixture of
rabbit anti-GFP and guinea pig anti-GlyT2 (1 mg/ml each) diluted
with 1% BSA/0.004% saponin/PBS overnight, and with 1.4 nm
gold particles-conjugated goat anti-rabbit IgG (Nanogold; Nanop-
robes) for 2 hr. Immunogold particles were intensified with a silver
enhancement kit (R-Gent silver enhancement kit, Aurion). Sections
were further incubated with biotinylated donkey anti-guinea pig
IgG (Jackson ImmunoResearch) for 2 hr, and streptavidin-perox-
idase complex for 30 min (Nichirei). Immunoreaction was visual-
ized with DAB, and then sections were treated with 1% osmium
tetroxide for 15 min, stained with 2% uranyl acetate for 30 min,
dehydrated, and embedded in Epon 812. Photographs were taken
with an H-7100 electron microscope (Hitachi).
Statistical analysis
Data were analyzed by unpaired Student’s t-test, using the Stat
View 4.5 software package (Abacus Concepts, Berkeley, CA). A
value of p,0.05 was considered statistically significant.
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Figure S1 Representative 5 h dark/light period hypnograms for
mice after saline and glycine administration. The shaded areas
represent the dark period. W, awake; NR, non-rapid eye
movement (REM) sleep; R, REM sleep. Glycine administered
mice showed fragmentation of sleep/wake states in dark phase.
(TIF)
Table S1 Numbers of orexin neurons with or without Fos
immunoreactivity in nuclei after glycine or saline administration.
Mice were administered with glycine or saline at ZT0 or ZT12,
and sacrificed for immunostaining at ZT3 or ZT15, respectively.
(TIF)
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